Expression ofHer2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma

Abstract

The expression of the Her2/neu gene product p185 was retrospectively analyzed in 58 patients with gastric carcinoma. The results were correlated to various clinicopathological and prognostic factors. Positive membrane staining for p185 could be detected in 38% of the patients (22/58). Membrane staining was significantly greater in well and moderately differentiated tumors of the intestinal type when compared with poorly differentiated lesions and carcinomas of the diffuse type (P less than 0.01). Positive membrane staining did not correlate with site and tumor stage, but T1 lesions had less membrane staining than more advanced primary tumors. Overall survival showed no difference between p185-positive and negative cases. Multivariate analysis defined a subgroup of curatively resected patients with stage III and IV disease that had a statistically significant poorer survival when p185 was overexpressed (P = 0.005). Overexpression of the Her2/neu product p185 appears to be associated with intestinal-type gastric carcinoma and may help in identifying a subset of patients at increased risk for shorter survival.

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer

“…Our top-ranked gene, ERBB2, is amplified and overexpressed in many cancers, including breast (31), ovary (31), colon (32), bladder (33), non-small-cell lung (34), and gastric cancer (35), and is a poor prognostic factor in certain cancer types (36,37). Several HER2 inhibitors, either tyrosine kinase inhibitors or monoclonal antibodies, are already in clinical use and are invaluable drugs in the treatment of breast cancer.…”

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

“…HER2, which is one of a family of trans-membrane-type epidermal growth factor receptors, is over-expressed in many human malignant neoplasms, such as breast, 23) ovary, 24) endometrium, 25) lung, 26) stomach, 27) colon, 28) esophagus, 29) bladder 30) and pancreas. 31) Also HER2 protein over-expression was reported as a prognostic factor in patients with breast, 8) endometrium, 9) urinary bladder, 11) pancreas 13) and non-small cell lung cancer.…”

Genomics of Squamous Cell Lung Cancer

“…Overexpression of HER2 contributes to the pathogenesis of many cancers including breast, ovarian, gastric, and salivary gland cancers [111][112][113][114]. Stephens et al reported mutations in ERBB2 kinase domain in 4% of the tumor samples from patients with lung cancer [115].…”